ProShare Advisors’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $850K | Sell |
15,376
-1,382
| -8% | -$76.4K | ﹤0.01% | 877 |
|
|
2025
Q1 | $810K | Sell |
16,758
-3,699
| -18% | -$179K | ﹤0.01% | 872 |
|
|
2024
Q4 | $790K | Buy |
20,457
+4,776
| +30% | +$184K | ﹤0.01% | 1022 |
|
|
2024
Q3 | $706K | Buy |
15,681
+4,411
| +39% | +$198K | ﹤0.01% | 936 |
|
|
2024
Q2 | $391K | Sell |
11,270
-3,075
| -21% | -$107K | ﹤0.01% | 1119 |
|
|
2024
Q1 | $415K | Buy |
14,345
+1,206
| +9% | +$34.9K | ﹤0.01% | 1199 |
|
|
2023
Q4 | $301K | Buy |
13,139
+1,957
| +18% | +$44.9K | ﹤0.01% | 1374 |
|
|
2023
Q3 | $187K | Buy |
11,182
+427
| +4% | +$7.12K | ﹤0.01% | 1494 |
|
|
2023
Q2 | $297K | Buy |
10,755
+1,869
| +21% | +$51.6K | ﹤0.01% | 1277 |
|
|
2023
Q1 | $204K | Buy |
+8,886
| New | +$204K | ﹤0.01% | 1435 |
|
|
2022
Q2 | – | Sell |
-13,399
| Closed | -$317K | – | 2051 |
|
|
2022
Q1 | $317K | Sell |
13,399
-3,090
| -19% | -$73.1K | ﹤0.01% | 1588 |
|
|
2021
Q4 | $564K | Buy |
16,489
+597
| +4% | +$20.4K | ﹤0.01% | 1363 |
|
|
2021
Q3 | $282K | Sell |
15,892
-2,729
| -15% | -$48.4K | ﹤0.01% | 1593 |
|
|
2021
Q2 | $836K | Buy |
18,621
+3,254
| +21% | +$146K | ﹤0.01% | 1140 |
|
|
2021
Q1 | $398K | Buy |
15,367
+2,492
| +19% | +$64.5K | ﹤0.01% | 1609 |
|
|
2020
Q4 | $260K | Buy |
+12,875
| New | +$260K | ﹤0.01% | 1706 |
|